Canada - English - Health Canada

emd serono, a division of emd inc., canada - tepotinib (tepotinib hydrochloride) - tablet - 225mg - tepotinib (tepotinib hydrochloride) 225mg - antineoplastic agents

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - tepotinib hydrochloride hydrate eqv tepotinib - tablet, film coated - tepotinib hydrochloride hydrate eqv tepotinib 225mg

European Union - English - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - carcinoma, non-small-cell lung - antineoplastic agents - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - tepotinib hydrochloride - tablet - 225mg

Israel - English - Ministry of Health

merck serono ltd - tepotinib as hydrochloride hydrate - film coated tablets - tepotinib as hydrochloride hydrate 225 mg - tepotinib - tepmetko is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) harbouring a met tyrosine kinase receptor exon 14 (metex14) skipping mutation.